Оставьте отзыв

ММГ Бизнес Консалтинг: маркетинговые исследования рынков

Маркетинговые исследования

• Более 450 успешных исследовательских проектов за последние 9 лет
• Входим в ТОП 5 национальных исследовательских компаний страны по оборотам
• Проводим исследования зарубежных рынков

Подробнее
image01

Анализ рынка

• Занимаемся анализом рынков с 1996 года
• Анализируем тенденции на украинском и зарубежных рынках
• Работаем с группой экспертов из 800 человек для выявления тенденций развития рынков

Подробнее
image01

Маркетинговый консалтинг

• Разработали рекомендации для более 100 украинских и зарубежных компаний
• Гарантируем увеличение продаж на 5-30% в месяц
• Даем финансовую гарантию достижения результата

Подробнее
image01

Получите 10 ценных подарков для Вашего бизнеса

• Подпишитесь на рассылку ММГ Консалтинг
• Заберите сразу 10 ценных подарков для Вашего бизнеса
• Получайте полезные советы по маркетингу и продажам каждую неделю

Подробнее
image01


Leap into a better future
Editor: Dmitri Rodenko
Type: Review
Viewed: 6606 раз(а)
Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10Average visitor rating of 6.8/10

Is this article interesting?    No Yes!   Vote » 

  
Leap into a better future

Every Ukrainian citizen annually spends an average of US $26-27 in retail prices for medications. For comparison, citizens of EU member countries neighboring with Ukraine spend around US $100-140 on purchasing medicines. Ukraine’s pharmaceuticals market continues to develop gradually and confidently: its last year’s volume amounted to US $1.25-1.3 bn. This year, its growth in money equivalent has been registered at 27-28%.

Viktoria Presnyakova, head of the representative office of RMBC Consulting, explains that the leap of the domestic pharmaceuticals industry by the presence of a powerful research and development base, strengthening of the positions of Ukrainian manufacturers and regulation of the system of state purchases of expensive medications for the treatment of HIV/AIDS, tuberculosis, pancreatic diabetes and oncological diseases.

Ihor Khmilevskiy, Chief of the External Information Service of the Morion Consulting Company, assured that by 2010, the volume of the pharmaceuticals market could triple to US $3.8-3.9 bn with an average growth of 25% annually.

However, in the opinion of Oleh Feldman, General Director of Comcon-Pharma Consulting, there are a number of factors that could affect the development of the industry such as the low consumption level of medications per capita of the population, disproportion between volumes of consumption of medications among residents of large regional centers and remote villages, the absence of systematic investments, excessive involvement of the state in the process of market regulation, a possible increase in the prices for raw materials and the material technical base of enterprises and the lack of trust of the population to advertising of medicines.

In the land of “pharmaceutical” giants

There are some 700 pharmaceutical companies operating in Ukraine, including 6 powerful Ukrainian companies producing over 70% of the pharmaceutical products manufactured in the country. In particular:

• Darnytsya (Kyiv) manufactures over 215 types of medicines, 500 mn vials, 4 bn packages of pills, 30 mn flasks of sterile antibiotics and 8.5 mn tubes of ointments;

• Borshchahivskiy Chemical-Pharmaceutical Plant (Kyiv) manufactures over 120 types of medicines in 10 pharmaceutical- therapeutic groups, the whole range of anti-tuberculosis medications, 200 mn packages of pills, 15 mn antibiotics in capsules and 14 mn sterile antibiotics in flasks;

• StirolBioPharm (Horlivka, Donetsk oblast) was built by the Canadian company Western Industrial Group. It manufactures 950 mn pills and capsules per year. It was the first and only enterprise in the country, which is certified by the ISO 9002 standard and fully complies with GMP international standards;

• Farmak (Kyiv) manufactures some 150 types of medicines and exports 11-15% of its products to Russia, CIS and Baltic countries, Bulgaria and Poland. The marketing strategy of the companies lies in active promotion of medications for endocrinology, cardiology, rheumatology, oncology and ophthalmology;

• Zdorovya (Kharkiv) produces over 150 types of medications of all pharmaceutical-therapeutic groups of ATC- classification, including original medicines produced on the basis of amino acids, herbs and generic medicines. Recently, the company received the prestigious European Quality Award from Oxford’s Europe Business Assembly.

• the new corporation Arterium, which was formed in the summer of 2006 as a result of the merger of two large plants – KyivMedPreparat and Lviv’s HalychPharm. This alliance turned out to be rather successful, as the growth in the company’s sales on the Ukrainian market totals 40% and it is fourth in the rating of pharmaceutical companies offering medicines in 11 out of 14 existing pharmaco-therapeutic groups.

According to the company’s CEO Denys Hartsylov, the merger of the two companies is an optimal combination of resources and possibilities for competing with foreign and transnational pharmaceutical companies, as well as with its largest domestic competitors Darnytsya and the Borshchahivskiy Plant.

Formulas of success

In order to receive the possibility of accessing leading pharmaceutical markets of the world and developing a national project for the prosperity of Ukrainian manufacturers in conditions of co-existence with foreign companies, Farmak General Director Fila Zhebrovska has proposed solution of the following tasks as quickly as possible:

• form a viable Association of Pharmaceuticals Producers of Ukraine;
• introduce a scientifically substantiated and transparent system of formulas;
• create a mechanism of state compensation of expenses for purchasing medicines;
• harmonize the Law of Ukraine on Medications with Directive 2001/83 of the European Parliament and EU Council from November 6, 2001 On the Code of Laws related to Medicinal Products for Human Consumption, supplemented by a new Directive 2004/27;
• starting from 2009, register only those medicinal products, the production of which is done according to international GMP standards – i.e. modernization of production lines, improvement of technical control, automation of processes and training of personnel;
• shorten the procedure for registration of reproduced medicinal products;
• bring price formation and the excise duty for medicinal alcohol in line with the current standards of the European Union;
• develop proposals on introduction of a differentiated VAT rate for medications.

While the reform of the pharmaceutical industry is under way, some domestic enterprises will be acquired by foreign ones. At least three generic companies – Polfarma (Poland), Pliva (Croatia) and Octapharma AG (Switzerland) – have been showing great interest in this.

Mykola Demydov, Director of the Center for Marketing Studies at Pharmexpert, advises Ukrainian companies to get rid of the information vacuum in order to attract foreign investors, because the vacuum prevents the latter from determining the market value of these companies. The problem is that the shares of local pharmaceutical companies are not quoted on stock exchanges and appraisals of different expert organizations could differ substantially. In addition to that, foreigners are interested in not only buying businesses as such (trademarks and shares on the market), but also production capacities.

Background

Distribution of shares on the pharmaceuticals market of Ukraine among companies leading by sales volumes of medicines:

Sanofi-Aventis (France) – 4.7%
Darnytsya (Ukraine) – 4.1%
Menarini Group (Italy) – 4%
Arterium (Ukraine) – 3.8%
Borshchahivskiy
Chemical-Pharmaceutical
Plant (Ukraine) – 2.9%
Farmak (Ukraine) – 2.6%
KRKA (Slovenia) – 2.6%
GlaxoSmithKline
(Great Britain) – 2.6%
Zdorovya (Ukraine) – 2.5%
Gedeon Richter 
(Hungary) – 2.3%
Other companies – 67.9%

Commentary

Viktor Shafranskiy, Head of the Representative Office of the French pharmaceutical company Beaufour Ipsen in Ukraine:

“The huge prospects of the pharmaceuticals market are directly connected to Ukraine’s integration into the WTO, which would mean liberalization of protectionist policy, regulation of trade aspects of intellectual property rights for patents, appearance of high quality, inexpensive medications, unlimited access to the world markets of Ukrainian produced medicines of the GMP standard, a decrease of customs duties and tariffs on imported products, stiffening of competition and improvement in the quality of medicines through the presence of foreign pharmaceutical companies, distributors and retail companies.”

Vitaliy Kyryk, Head of the Representative Office of the German pharmaceutical
company Ratiopharm in Ukraine:

“I believe that the following is required to have or do for full-fledged formation of the Ukrainian pharmaceutical industry in conditions of a competitive market: own a balanced portfolio of prescription and non-prescription drugs, diversify assortment of products, conduct an effective promotion, start a process of consolidation and vertical integration in the sphere of distribution and the drug store business, establish tough barriers to prevent imitations, increase budget allocations for healthcare, approve basic therapeutic standards and, what is most important, develop the commercial sector of medicine.”

Volodymyr Ihnatov, Head of the Representative Office of the English-Swedish
pharmaceutical company AstraZeneca in Ukraine:

“The situation on the domestic pharmaceuticals market can develop by two scenarios. The first, pessimistic scenario, envisages preserving complicated problems that scare away foreign investment and innovation companies. Such problems include the non-operable system of medical insurance, patients spending a lot of money on low quality medicines, the government financing only several priority programs and legal regulation that remains unchanged.

The second, optimistic scenario will happen under condition of introduction of medical insurance, observance of intellectual property rights and improvement in the investment attractiveness of pharmacological business.”

By Volodymyr Tyravskiy
Source: http://weekly.com.ua


Страницы:  1  


Related articles


Real estate boom = investment boon


Related linksForum

This article is discussed at the forum.
Go.

Related reports

There are no related reports at the Research Shop.




  Comments   Add comment! | All comments (0)
    Your comment will be the first!




 

Карта сайта

Рейтинг@Mail.ru


Все права защищены © 2003-2017, Международная Маркетинговая Группа Украина
.

При публикации материалов сайта Международной Маркетинговой Группы в интернете обязательна гиперссылка на главную страницу сайта http://www.marketing-ua.com, при использовании материалов в печатных изданиях обязательно упоминание "Международная Маркетинговая Группа, http://www.marketing-ua.com"
Международная Маркетинговая Группа Украина
Украина, Киев Фрунзе, 69В , 6 этаж
Tel:+38-044-331-14-14, Tel:+38-044-492-38-28